LKB1 inactivation in NSCLC is associated with a reduction of CD8+ T lymphocytes and a higher density of the immune-suppressive cell population, defining an “inert” or cold tumor immune microenvironment, that promotes resistance to PD-1/PD-L1 inhibitors (43, 50). The gene discussed is STK11; the disease is neoplasm.